TGFB2 and breast cancer: We conclude that this SRC-Slug-TGFβ2 axis may contribute to chemotherapy resistance in an aggressive subpopulation of TNBC tumors, and targeting this pathway may help to improve outcomes for this aggressive breast cancer subtype.